Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Erbitux Sales to Exceed 1 Bil. Euro Mark
August 10, 2009
- Combination Drugs Interfere with Promotion of Generics: JSHP
August 10, 2009
- No. 3 and No. 4 CSOs to Merge
August 10, 2009
- Establish Regional Networks to Promote Use of Generics: Mr Kinoshita
August 10, 2009
- BUSINESS NEWS IN BRIEF
August 10, 2009
- BUSINESS NEWS IN BRIEF
August 3, 2009
- Can You Tell a Good Story?
August 3, 2009
- Doctors' Sources of Information on ARBs Investigated by So-net M3
August 3, 2009
- Medical Expenditures Up 1.9% to ¥34.1 Tril. In FY2008
August 3, 2009
- Eisai Submits First Application for E7389 in Switzerland
August 3, 2009
- Only 40% of Consumers Have Single Regular Pharmacies: JPA
August 3, 2009
- FDA Extends NDA Review for Alogliptin and ACTOS Combination
August 3, 2009
- Isentress Should Be Used in First-Line Therapy: Dr Hanabusa
August 3, 2009
- Sitagliptin, Sibutramine Recommended for Approval
August 3, 2009
- Exceptional NHI Price Maintenance System Benefits Patients: Mr Nagano
August 3, 2009
- Generics, Drug Pricing Not Included in DPJ's Manifesto
August 3, 2009
- REGULATORY NEWS IN BRIEF
August 3, 2009
- Share of Generics Up 1.9 Points to 18.0% on a Volume Basis
August 3, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 3, 2009
- Kure City to Save Over ¥100 Mil. by Generics Use-Promotion Notification Service
August 3, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…